Zheng Quan Shi Bao Wang·2025-11-26 00:49Company Overview - Olin Bio has submitted its application to list on the main board of the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [1] - The company focuses on the research, development, production, and commercialization of innovative vaccines, particularly targeting unmet medical needs in "super bacteria vaccines" and "adult vaccines" [1] - Olin Bio has successfully commercialized three products: adsorbed tetanus vaccine, Hib conjugate vaccine, and A and C group meningococcal polysaccharide conjugate vaccine [1] Market Position - According to a report by Zhi Shi Consulting, Olin Bio's adsorbed tetanus vaccine is expected to maintain a leading market position in China from 2022 to 2024, with a market share exceeding 80% in the batch release market [1] - The company possesses the most comprehensive pipeline of targeted vaccines against "super bacteria," including innovative candidates for Staphylococcus aureus, Helicobacter pylori, Pseudomonas aeruginosa, Acinetobacter baumannii, and Group A Streptococcus, all of which are classified as high or critical priority by the World Health Organization [1] Industry Growth - The market size for tetanus vaccines in China is projected to grow from RMB 200 million in 2019 to RMB 800 million by 2024, with a compound annual growth rate (CAGR) of 40.2% [2] - By 2035, the tetanus vaccine market is expected to reach RMB 2.6 billion, with a CAGR of 10.8% from 2024 to 2035, driven by an aging population and expanded applications [2] - The Hib vaccine market in China is anticipated to grow from RMB 500 million in 2024 to RMB 2.4 billion by 2035, with a CAGR of 15.7% [2] - The meningococcal vaccine market is expected to increase from RMB 2.6 billion in 2019 to RMB 2.7 billion by 2024, with a CAGR of 1.4%, and reach RMB 5.8 billion by 2035, with a CAGR of 7.0% from 2024 to 2035 [2]